Drug Profile
Cetuximab biosimilar - Sichuan Kelun Pharmaceutical Research Institute
Alternative Names: A-140; KL 140; Recombinant anti-EGFr antibodyLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Colorectal cancer
Most Recent Events
- 31 Jan 2024 Cetuximab biosimilar - Sichuan Kelun Pharmaceutical Research Institute is available for licensing as of 31 Jan 2024. https://www.kluspharma.com/contact
- 31 Jan 2024 Sichuan Kelun Pharmaceutical plans to launch A 140 in China market in the second half of 2024 or the first half of 2025
- 30 Jun 2023 Preregistration for Colorectal cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in China (IV)